GENE Genetic Technologies Ltd.

2.190.09 (+4.29%)
Close: September 16, 2019

2.17-0.02 (-0.91%)
After hours

Quote

Previous Close
$2.19
Day Range
$2.09-$2.22
52 Week Range
$1.56-$6.32
Volume
36,668
Avg Volume
122,324
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
-
Enterprise Value (EV)
$6.17B
PE Ratio
-
EV/EBITDA
-1261.96
Price/Sales
339,082.91
Price/Book
11.52
PEG Ratio
-

Financials

Revenue
$18.20K
Gross Profit
-$179.38K
EBITDA
-$4.89M
EPS, ttm
-$1.12
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
-
Debt to Equity
-
Debt
$6.17B
Cash
$1.50M
Net Debt
$6.17B

Performance

Beta
0.64
200 Day Moving Avg
$2.94
50 Day Moving Avg
$2.23
52 Week Change
-48.83%
YTD Change
-15.28%
1 Month Change
18.64%
3 Month Change
-17.97%
6 Month Change
-42.31%
1 Year Change
-50.93%
2 Year Change
-36.61%
5 Year Change
-87.65%

Share Count

Shares Outstanding
-

Genetic Technologies Ltd. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Paul Alexander Kasian

Website: http://www.gtgcorporate.com

Description: Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Employees: -